Treatment strategies for idiopathic interstitial pneumonias

Current Opinion in Pulmonary Medicine

Volumn 20, Issue 5, 2014, Pages 442-448

  Wells, Athol U ^a   Kokosi, Maria ^a   Karagiannis, Konstantinos ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

disease behaviour classification; idiopathic pulmonary fibrosis; nintedanib; pirfenidone

Indexed keywords

BIOPSY; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; FIBROSING ALVEOLITIS; HUMAN; IDIOPATHIC INTERSTITIAL PNEUMONIAS;

BIOPSY; DIAGNOSIS, DIFFERENTIAL; HUMANS; IDIOPATHIC INTERSTITIAL PNEUMONIAS; IDIOPATHIC PULMONARY FIBROSIS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84906046629     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0000000000000085     Document Type: Review

References (28)

1. Selman M, King TE Jr, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001; 134:136-151.
2. IFIGENIA Study Group. Demedts M, Behr J, Buhl R, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005; 353: 2229-2242.
3. Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011; 365:1079-1087
4. Pirfenidone Clinical Study Group in Japan. Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010; 35:821-829.
5. Noble PW, Albera C, Bradford WZ, et al., CAPACITY Study Group. Pirfe-nidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011; 377:1760-1769.
6. ASCEND Study Group. King TE Jr, Bradford WZ, Castro-Bernadini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370:2083-2092.
7. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370:2071-2082.
8. Martinez FJ, de Andrade JA, Anstrom KJ, et al., The Idiopathic Pulmonary Fibrosis Clinical Research Network. Randomised trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370:2093-2101.
9. Loomis-King H, Flaherty KR, Moore BB. Pathogenesis, current treatments and future directions for idiopathic pulmonary fibrosis. Curr Opin Pharmacol 2013; 13:377-385.
10. Raghu G, Anstrom KJ, King TE Jr, et al., The Idiopathic Pulmonary Fibrosis Clinical Research Network. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012; 366:1968-1977.
11. IPFnet Investigators. Lee JS, Collard HR, Anstrom K, et al. Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data in three randomised controlled trials. Lancet Respir Med 2013; 1:369-376.
12. Raghu G, Freudenberger TD, Yang S, et al. High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis. Eur Respir J 2006; 27:136-142
13. ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idio-pathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183:788-824.
14. Raghu G, Lynch D, Godwin JD, et al. Diagnosis of idiopathic pulmonary fibrosis with high-resolution CT in patients with little or no radiological evidence of honeycombing: secondary analysis of a randomised, controlled trial. Lancet Respir Med 2014; 2:277-284.
15. Fell CD, Martinez FJ, Liu LX, et al. Clinical predictors of a diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2010; 181: 832-837.
16. Morell F, Villar A, Montero MA, et al. Chronic hypersensitivity pneumonitis in patients diagnosed with idiopathic pulmonary fibrosis: a prospective case-cohort study. Lancet Respir Med 2013; 1:685-694.
17. Tashkin DP, Elashoff R, Clements PJ, et al., Scleroderma Lung Study Research Group. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354:2655-2666.
18. Hoyles RK, Ellis RW, Wellsbury J, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006; 54:3962-3970.
19. Travis WD, Costabel U, Hansell DM, et al., ATS/ERS Committee on idiopathic interstitial pneumonias. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013; 188:733-748.
20. Goh NS, Desai SR, Veerarhagavan S, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008; 177: 1248-1254.
21. Moore OA, Goh N, Corte T, et al. Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease. Rheumatology (Oxford) 2013; 52:155-160.
22. Ley B, Ryerson CJ, Vittinghoff E, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 2012; 156:684-691.
23. Ryerson CJ, Vittinghoff E, Ley B, et al. Predicting survival across chronic interstitial lung disease: the ILD-GAP model. Chest 2013; 145:723-728.
24. Fischer A, Brown KK, du Bois RM, et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol 2013; 40:640-646.
25. Sem M, Molberg O, Lund MB, Gran JT. Rituximab treatment of the anti-synthetase syndrome: a retrospective case series. Rheumatology (Oxford) 2009; 48:968-971.
26. Daoussis D, Liossis SN, Tsamandas AC, et al. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford) 2010; 49:271-280.
27. Keir GJ, Maher TM, Hansell DM, et al. Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy. Eur Respir J 2012; 40:641-648.
28. Keir GJ, Maher TM, Ming D, et al. Rituximab in severe refractory interstitial lung disease. Respirology 2014; 19:353-359.